Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02389829 · ClinicalTrials.gov registry record · Phase 4
Hydromorphone Versus Prochlorperazine + Diphenhydramine for Acute Migraine
A Phase 4 study of Migraine, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 127
- Enrollment target
- 1
- Study location
NCT02389829 is a Phase 4 study of Migraine that has completed, run by Montefiore Medical Center. The registered enrollment target is 127 participants, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02389829, a Phase 4 study of Migraine, has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 127 participants
- Enrollment target
- 1
- Study location
Study Summary
Opioids are commonly used to treat migraine in North American Emergency Departments. We are comparing efficacy and adverse events of hydromorphone, an opioid, to that of prochlorperazine, a dopamine antagonist with known efficacy in migraine. Prochlorperazine will be combined with diphenhydramine to prevent adverse events.
Conditions Studied
Interventions
- DRUG Hydromorphone
- DRUG Diphenhydramine
- DRUG Prochlorperazine
Study Locations (1)
New York
- Montefiore Medical Center--Einstein - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2015-03 |
| Est. Completion | 2016-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02389829
The ClinicalTrials.gov registry entry for NCT02389829 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (64% lower). The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 3 interventions - of which Hydromorphone is the first listed.
NCT02389829 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02389829 about?
NCT02389829 is a clinical study titled "Hydromorphone Versus Prochlorperazine + Diphenhydramine for Acute Migraine". Opioids are commonly used to treat migraine in North American Emergency Departments. We are comparing efficacy and adverse events of hydromorphone, an opioid, to that of prochlorperazine, a dopamine antagonist with known efficacy in migraine. Prochlorperazine will be combined with diphenhydramine to...
What is the current status of trial NCT02389829?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 127 participants. The study started on 2015-03. Estimated completion is 2016-10.
What conditions does trial NCT02389829 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT02389829?
The interventions under investigation include: Hydromorphone (DRUG), Diphenhydramine (DRUG), Prochlorperazine (DRUG).
Who is sponsoring clinical trial NCT02389829?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02389829 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
RECRUITING · Phase 4
-
Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications
RECRUITING · Phase 4
-
Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US
RECRUITING · Phase 4
-
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
RECRUITING · Phase 4
-
Nerivio Efficacy Under High-Frequency Use
ACTIVE NOT RECRUITING · Phase 4
-
Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.